Transfusion independence (TI) was significantly effective in the roxadustat-treated group [28] in pure red cell aplasia (PRCA) patients who resist to EPO (rHu-EPO) treatment due to antibodies against EPO, can also be improved by roxadustat [29, 30]. The gene discussed is EPO; the disease is Pure red cell aplasia.